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Background. Poor access to diagnosis stymies control of visceral leishmaniasis (VL). Antibody-detecting rapid
diagnostic tests (RDTs) can be performed in peripheral health settings. However, there are many brands available
and published reports of variable accuracy.
Methods. Commercial VL RDTs containing bound rK39 or rKE16 antigen were evaluated using archived
human sera from conﬁrmed VL cases (n = 750) and endemic non-VL controls (n = 754) in the Indian subcontinent
(ISC), Brazil, and East Africa to assess sensitivity and speciﬁcity with 95% conﬁdence intervals. A subset of RDTs
were also evaluated after 60 days’ heat incubation (37°C, 45°C). Interlot and interobserver variability was assessed.
Results. All test brands performed well against ISC panels (sensitivity range, 92.8%–100%; speciﬁcity range,
96%–100%); however, sensitivity was lower against Brazil and East African panels (61.5%–91% and 36.8%–87.2%,
respectively). Speciﬁcity was consistently > 95% in Brazil and ranged between 90.8% and 98% in East Africa. Perfor-
mance of some products was adversely affected by high temperatures. Agreement between lots and readers was good
to excellent (κ > 0.73–0.99).
Conclusions. Diagnostic accuracy of VL RDTs varies between the major endemic regions. Many tests performed
well and showed good heat stability in the ISC; however, reduced sensitivity against Brazilian and East African
panels suggests that in these regions, used alone, several RDTs are inadequate for excluding a VL diagnosis. More
research is needed to assess ease of use and to compare performance using whole blood instead of serum and in
patients coinfected with human immunodeﬁciency virus.
Visceral leishmaniasis (VL) is a parasitic disease trans-
mitted through the bite of an infected phlebotomine
sandﬂy [1]. The clinical syndrome is characterized by
fever, weight loss, splenomegaly, and pancytopenia
and is nearly always fatal if left untreated. Though vis-
ceral leishmaniasis is endemic in >60 countries, 90%
of the 200 000–400 000 annual cases occur in just 6
countries: Bangladesh, Brazil, Ethiopia, India, Nepal,
and Sudan [2].
Parasitological conﬁrmation remains the reference
standard for diagnosis but is not very sensitive unless
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a spleen puncture is performed. The invasiveness and poten-
tially fatal complications associated with splenic aspiration has
motivated the development of noninvasive serological tests
such as direct agglutination test (DAT) [3] and lateral ﬂow im-
munochromatographic tests (ICT), commonly referred to as
rapid diagnostic tests (RDTs). To be useful, VL RDTs must
have adequate (1) sensitivity to detect a high proportion of
clinical cases, (2) speciﬁcity to accurately discriminate VL
from other relevant disease conditions, (3) thermal stability
for accuracy to be maintained after transport and storage in
ambient conditions, and (4) ease of use to allow the correct
interpretation of results. A meta-analysis [4] and a multicenter
evaluation [5] corroborated earlier ﬁndings of high diagnostic
accuracy of the rK39 ICT and led to its adoption as a diagnos-
tic test in the Indian subcontinent VL Elimination Initiative.
The enthusiasm and rapid uptake of RDTs for VL in the
Asian region has prompted a surge of commercial tests target-
ing serum antibodies to rK39 and other antigens (eg, rKE16)
[6]. However, in other endemic regions such as East Africa,
reports of lower test sensitivity [7–9] have left the role of
RDTs less clear. Moreover, there are few, if any, reports of di-
agnostic accuracy in the peer-reviewed literature for tests other
than the Kalazar Detect (Inbios International) and DiaMed-
IT LEISH (Bio-Rad Laboratories) and equally few head-to-
head comparisons. Essential characteristics as heat stability are
rarely assessed. As independent data on how well these assays
meet criteria are lacking in countries without regulation by
national testing authorities, the UNICEF/World Bank/United
Nations Development Programme/World Health Organization
(WHO) Special Programme for Research and Training in
Tropical Diseases (TDR) coordinated a multiregional head-to-
head laboratory-based evaluation of 4 commercially available
RDTs in 3 global regions of VL endemicity using well-charac-
terized panels of human sera; a ﬁfth RDT was included in the
Indian subcontinent.
METHODS
Site Selection
In 2008, TDR issued a public request for applications for any
laboratory interested in becoming a member of a VL laboratory
network to perform the VL RDT evaluation. Before imple-
menting the evaluation, each laboratory had DAT refresher
training and passed a DAT proﬁciency assessment. All techni-
cians underwent training in good clinical laboratory practices
and sites were independently monitored.
Assay Selection
An extensive search of VL RDTs available was performed
using both generic (Google) and scientiﬁc (PubMed) Internet-
based search engines. In March 2009, companies selling VL
RDTs were contacted by email and the evaluation was publi-
cally announced through an open call for expression of inter-
est for tests that ﬁt the following inclusion criteria: (1) rapid—
test result available in 15 minutes; (2) simple—test can be per-
formed with minimal equipment and training; and (3) easy to
interpret—cassette or strip format with visual read-out. Manu-
facturers who responded were required to (1) provide a certiﬁ-
cate of quality manufacturing, either ISO 13485:2003 or US
Food and Drug Administration Title 21 CFR certiﬁcation; (2)
supply sufﬁcient quantities of products (lot 1: 1849; lot 2:
1794 [exception for OnSite Leishmania Ab Rapid Test Strip,
CTK Biotech, which provided lot 1: 623 and lot 2: 598]); and
(3) a signed conﬁdentiality agreement with the WHO permit-
ting the publication of results in the public domain.
Evaluation Panel
Each laboratory assembled a performance panel using locally
archived and depersonalized sera. Prior to serum banking, VL
disease was conﬁrmed parasitologically (from spleen, bone
marrow, or lymph node) by microscopy and/or culture. Ar-
chived sera were characterized by DAT (KIT, lot 0904) (titer
between 1:100 and 1:102 400 antigen dilution) as low,
medium, or high antibody titer. All healthy endemic control
samples and potentially cross-reactive samples including
malaria, Chagas disease, tuberculosis, and cutaneous leish-
maniasis were DAT negative (<1:3200 antigen dilution)
(Table 1).
Samples were thawed once and aliquoted in volumes re-
quired to evaluate all RDTs included in the evaluation and
were then stored at −70°C until testing.
Sample Blinding
Daily, samples (in sets of 10–20) were randomized and rela-
beled with study codes by a study team member not involved
in the assessment of the RDTs at any stage. The study code
key was kept in a secure location and provided at the comple-
tion of testing.
Sample Size
We aimed for a sensitivity and speciﬁcity estimate pooled at
regional level. Assuming a true sensitivity of 95%, a sample
size of 250 VL cases in each endemic region is required to
assure with a power of 80% and a conﬁdence level of 95% that
the lower margin of the conﬁdence interval (CI) is at least
90%. The same applies to speciﬁcity; in this case the sample
consists of nondiseased controls. We therefore selected, per
region, 250 cases and 250 controls; included among the latter
were samples of 210 healthy endemic controls and of 40 pa-
tients with potentially cross-reactive, endemic disease condi-
tions (Table 1, Supplementary Table 1).
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RDT Testing Methodologies
Daily sample sets were removed from the −70°C freezer and
brought to room temperature. Each sample was tested once
against each product according to manufacturers’ instructions.
RDT envelopes were opened immediately before use. The
speciﬁed volume of serum was dispensed onto the RDT by
micropipette. The buffer was applied using the dropper pro-
vided. Results were read and recorded on a standardized form
by a ﬁrst technician at the minimum reading time and within
30 minutes the test was read and recorded by a second techni-
cian, blinded to the reading of the ﬁrst. Results of test and
control lines were recorded as positive or negative by each
technician. More speciﬁcally, band intensity was recorded for
each test, based on standardized charts. If the control line was
recorded as absent by either technician, the same sample was
tested once against a new RDT. If the control line was still
absent, the test result was recorded as invalid.
In each of the 9 evaluation centers, for each test kit, the
same lot was used. All RDTs from the ﬁrst lot were tested
before 25% of panel samples, including all 3 infection status
categories, were retested against a second lot of the same test
kit, to assess lot-to-lot variability.
Thermal Stability
In 1 laboratory per region, each RDT, excluding 1 product
(Signal KA) not recommended for room temperature storage,
was tested against a panel of 24 serum samples (20 VL cases
and 4 negative controls) at day 0 as a baseline measure; then
stored in original packaging in calibrated incubators of 4°C,
37°C, and 45°C and tested (against the same panel) on day 60.
Ethics
Each laboratory participating in the evaluation obtained ap-
proval from the local ethics board and the WHO Research
Ethics Committee.
Data Management and Analysis
Data were entered into an Epi Info database using a double
data entry procedure. Data ﬁles were compared to identify
typing errors. For data analysis we used Stata/IC version 10.1
(StataCorp, College Station, Texas). Diagnostic accuracy was
calculated using RDT results from the ﬁrst reading at the
minimum reading time. We calculated proportions with 95%
CIs [10, 11]. As a measure for reproducibility, we used Cohen
κ coefﬁcient [11]. These were interpreted following Landis
and Koch: 1.00–0.81 excellent, 0.80–0.61 good, 0.60–0.41
moderate, 0.40–0.21 weak, and 0.20–0.00 negligible agreement
[12]. Thermal stability results were reported as proportions of
positive results for case samples and negative results for
control samples, as were proportions of invalid results.
RESULTS
Site Selection
Twenty-two applications were received and 9 laboratories in
the Indian subcontinent (n = 4), South America (n = 2), and
Eastern Africa (n = 3) were chosen based on several criteria
including access to patients, geographical location, laboratory
facilities, expertise, and experience with RDTs. Laboratories
were Rajendra Memorial Research Institute of Medical Scienc-
es, India; Institute of Medical Sciences, Banaras Hindu Uni-
versity, India; Parasitology Laboratory, International Centre
for Diarrhoeal Disease Research, Bangladesh; B. P. Koirala In-
stitute of Health Sciences, Nepal; Kenya Medical Research In-
stitute, Kenya; Faculty of Medicine, University of Khartoum,
Sudan; Institute Endemic Diseases, University of Khartoum,
Sudan; Laboratório de Soroepidemiologia e Imunobiologia In-
stituto de Medicina Tropical de São Paulo, Brazil; and Centro
de Pesquisas René Rachou, Fundação Oswaldo Cruz, Fiocruz,
Brazil. The Institute of Tropical Medicine, Belgium (ITM),
was contracted as an independent partner to coordinate logis-
tics of RDT supplies, as well as proﬁciency testing in the DAT
Table 1. Performance Evaluation Panel Characteristics
Sample Size DAT Titer, Cases (%)
Average Age of
Patients (y) HIV Statusa (%)
Cases HEC
Non-VL Disease
Condition Controls Low (≤100)
Medium
(1:200–
1:6400)
High
(>1:6400) Case Controls Unknown
Known
Positive Negative
East Africa 250 210 40 0.4 8.8 90.8 14 20 47.2 0 52.8
Brazil 237–250 206–209 42–45 0.0 11.6 88.4 19 27 98.6 0 1.4
ISC 250 210 39 0.0 3.2 96.8 24 31 50.8 0.5 48.7
Abbreviations: DAT, direct agglutination test; HEC, healthy endemic control; HIV, human immunodeficiency virus; ISC, Indian subcontinent; VL, visceral
leishmaniasis.
a Includes cases and controls combined.
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for VL laboratories alongside the Royal Tropical Institute,
Netherlands.
Assay Selection
The survey identiﬁed 3 suppliers, and a fourth (CTK Biotech)
responded independently to the public expression of interest
after the deadline. In total, 5 commercial RDTs that met the
inclusion criteria were included in the evaluation (Table 2).
RDT Shipments
All manufacturers shipped tests from 2 lots to ITM. Here, the
RDTs were repackaged for courier shipment to each laborato-
ry with at least 1 temperature monitoring device and, if appli-
cable, cooling agents and insulating packaging.
A shipment destined to 1 evaluation center in India was
delayed and temperature log data revealed that all RDTs
(except OnSite Leishmania Ab Rapid Test Strip [CTK
Biotech], which was shipped separately on different dates) in
the shipment were subjected to temperatures exceeding manu-
facturers’ recommendations (>30°C) for a period of 4 weeks.
An ad hoc meeting of the VL Network recommended the ex-
clusion of Signal-KA (Span Diagnostics) from the Banaras
Hindu University center because of its requirement for storage
between 2°C and 8°C. All other tests were included at the
center. Upon arrival, tests were immediately stored according
to the manufacturers’ instructions.
Diagnostic Accuracy
Sensitivity and speciﬁcity based on pooled data per region per
test are presented in Table 3. Results were highly comparable
intraregionally (data not shown) but variable between regions.
On the Indian subcontinent all tests performed well, with high
sensitivity, which ranged from 92.8% (95% CI, 88.9%–95.4%;
CrystalKA) to 100% (95% CI, 97.9%–100%; Signal KA) and
high speciﬁcity, which ranged from 99.2% (CI, 97.1%–99.8%;
CrystalKA) to 100% (95% CI, 97.8%–100%; Signal KA).
However, in East Africa and Brazil lower sensitivity was ob-
served, which ranged from 36.8% (95% CI, 31.1%–42.9%;
CrystalKA) to 92% (95% CI, 87.8%–94.8%; IT LEISH). The
sensitivity of IT LEISH was signiﬁcantly better than any other
products evaluated in East Africa (P < .0001) and in Brazil
(P = .013).
Furthermore, in these 2 regions speciﬁcity was generally
higher than sensitivity and more consistent, ranging from
90.8% (95% CI, 86.6%–93.8%; Kalazar Detect) to 98.8% (95%
CI, 96.6%–99.6%; Signal KA).
There were no major differences in speciﬁcity between
samples from healthy endemic controls and those of potential-
ly cross-reactive controls in any of the regions. We therefore
present speciﬁcity results based on all control samples
combined.
Lot-to-Lot and Interobserver Variability
In general, agreement of test results between lots and readers
was high; with a few exceptions, points ranging from even the
lower margins of the CIs can still be considered “good” agree-
ment (Supplementary Tables 2 and 3).
Thermal Stability
In the Indian subcontinent all tests assessed showed excellent
baseline performance, which was maintained after incubation
for 60 days at 4°C and 37°C. However, one product’s perfor-
mance (IT LEISH) was seriously affected by post–60 day incu-
bation at 45°C, returning 100% invalid results (n = 24). In East
Africa and Brazil, suboptimal baseline performance of 2 tests
suggests samples may be at the limit of detection of some
products and therefore variations at baseline probably reﬂect
intertest variation. Nonetheless, in Brazil 2 products appear to
be stable and the other (IT LEISH), despite the best baseline
performance, showed reductions in performance at 35°C and
45°C but no invalid results as reported in both the Indian sub-
continent and East Africa (Supplementary Table 4). In East
Africa, test performance appeared to improve for one product
(80% detection at baseline to 100% detection after 60 days at
45°C).
DISCUSSION
This study is the ﬁrst global head-to-head comparison of per-
formance of VL RDTs in 3 endemic regions. In the ISC, our
results reﬂect previous reports of high accuracy of rK39 RDTs;
however, our study extends to rKE16-based products and an
rK39 commercial test not previously independently evaluated.
Overall, our ﬁndings illustrate that in the ISC several RDTs
demonstrated high sensitivity and speciﬁcity (Table 3). Fur-
thermore, performance of these products did not seem to be
signiﬁcantly affected by heat stress induced, inadvertently,
during transport to one center in India. This is a reassuring
ﬁnding, as these circumstances can be expected to occur regu-
larly in routine settings. However, in East Africa and Brazil,
the tests performed with variable sensitivity but high speciﬁc-
ity (3 of 4 tests, >95%). In Brazil and in 2 sites in East Africa,
the rKE16-based products appeared to perform less well than
rK39 products. This may be partially explained by the fact
that rKE16 antibody-detecting tests are based on a recombi-
nant antigen (Ld-rKE16) from a newly isolated Indian strain
of Leishmania donovani (MHOM/IN/KE16/1998), whereas
rK39 is based on Leishmania infantum, the species causing
VL in Brazil [13].
Differences in product performance between regions is
likely attributable to parasite diversity and/or differences in
antibody concentrations which may in turn be linked to dif-
ferent age patterns, immune response, and nutritional status
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Table 2. Characteristics of Visceral Leishmania Rapid Diagnostic Tests Included in the Evaluation
Product Manufacturer
Catalog
No.
Lateral
Flow
Format Lot No.
Storage
Temperature
Shelf
Life
Control
Line
Test Line,
Bound
Antigen
Sample
Volume (µL)
Buffer
Quantity
(Drops)
Minimum
Reading
Time (min)
Maximum
Reading
Time
CrystalKA Span Diagnostics, Ltd 56FT101 Dipstick R2009004 4°C–30°C 18 mo Yes rKE16 20 5 15 30
R2009003
DiaMed-IT
LEISH
Bio-Rad Laboratories 710124 Cassette 46240.27.01 2°C–30°C 16 mo Yes rK39 8–12 (10 μL
mark on
pipette)
Step 1: 1
(conjugate
well), Step
2: 4 (wash
well)
5 Not
specified
46240.28.01
Kalazar Detect InBios International,
Inc
INS105 Dipstick KE 2108 RT (20°C–28°
C)
24 mo Yes rK39 20 3 10 10
KE 1047
Signal–KA Span Diagnostics Ltd 56FT100 Cassette 4000002561 2°C–8°C 12 mo Yes rKE16 Mix 1 (20 μL)
part serum
with 4 parts
normal
saline, then
use 50 μL.
Step 1: 2
Step 2: 2
Step 3: 3
2 10
4000002604
OnSite
Leishmania
Ab Rapid Test
CTK Biotech Inc RO122S Dipstick F0317G2 2°C–30°C 18 mo Yes rK39 5 2 15 15
F0318G2
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Table 3. Sensitivity and Speciﬁcity of Rapid Diagnostic Tests, All Regions
Product Manufacturer
East Africa Brazil Indian Subcontinent
Sensitivity (95% CI)
(n = 250)
Specificity (95% CI)
(n = 250) Sensitivity (95% CI) Specificity (95% CI)
Sensitivity (95% CI)
(n = 250)
Specificity (95% CI)
(n = 249)
CrystalKA Span
Diagnostics
36.8% (31.1%–42.9%) 98.0% (95.4%–99.1%) 61.5% (55.2%–67.4%)a 98.4% (95.9%–99.4%)b 92.8% (88.9%–95.4%) 99.2% (97.1%–99.8%)
DiaMed-IT
LEISH
Bio-Rad
Laboratories
87.2% (82.5%–90.8%) 96.4% (93.3%–98.1%) 92.0% (87.8%–94.8%)c 95.6% (92.2%–97.5%)d 98.8% (96.5%–99.6%) 97.6% (94.8%–98.9%)
Kalazar Detect InBios
International,
67.6% (61.6%–73.1%) 90.8% (86.6%–93.8%) 84.7% (79.7%–88.7%)e 96.8% (93.9%–98.4%)f 99.6% (97.8%–99.9%) 96.0% (92.8%–97.8%)
Signal–KA Span
Diagnostics
73.2% (67.4%–78.3%) 96.4% (93.3%–98.1%) 79.2% (73.7%–83.8%)g 98.8% (96.6%–99.6%)h 100% (97.9%–100%)i 100% (97.8%–100%)j
OnSite
Leishmania
Ab Rapid
CTK Biotech NA NA NA NA 99.6% (97.8%–99.9%) 96.8% (93.8%–98.4%)
Abbreviations: CI, confidence interval; NA, not applicable.
a n = 244.
b n = 249.
c n = 237.
d n = 248.
e n = 249.
f n = 252.
g n = 250.
h n = 254.
i n = 175.
j n = 170.
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of patient. The average patient age of VL cases in each region
was 24 years, 14 years, and 19 years in the Indian subconti-
nent, East Africa, and Brazil, respectively. Furthermore, the
proportion of DAT titers >1:102 400, representing very high
antibody response in the Indian subcontinent, was 58%, drop-
ping to 40% and 27% in East Africa and Brazil, respectively;
and may highlight differential antibody response/production
to infection in different geographical areas.
In addition, subgroup analysis based on human immunode-
ﬁciency virus (HIV) status could not be completed owing to
limited availability of information on HIV status of patients.
HIV and VL coinfections are important to consider in VL
endemic areas and test reliability is known to fall in some of
these cases [14].
In all regions, agreement between lots or batches of the
same product was good to excellent (κ = 0.73–0.98) according
to Landis and Koch [12], and agreement between readers
(second reading within 30 minutes of the ﬁrst) was excellent
(κ > 0.9). All manufacturers in this evaluation have current
ISO 13485:2003 certiﬁcation, a standard designed to give as-
surance of consistency of quality of ﬁnal product; however, it
cannot be guaranteed that the results here will predict results
from different RDT lots. Ideally, quality control materials
should be developed so that manufacturers and procurers
alike can assess test lots prior to purchase to ensure that ex-
pected performance is maintained. Furthermore, training and
supervision of operators must be implemented on a program-
matic level to ensure the quality of testing (preparation and
interpretation) at the point of care.
VL is endemic in regions where daytime temperatures can
regularly exceed 30°C or 40°C, so it is likely that RDTs will be
exposed to temperatures above the manufacturers’ recommen-
dations (usually 30°C) during transport, storage, or use in
ﬁeld settings. Heat is known to diminish the performance of
some malaria RDTs [15] but there are no published reports
on the thermal stability of VL RDTs. Our assessment does not
mimic the ﬂuctuating heat and humidity conditions in real-
life settings, nor does it necessarily predict long-term stability
in ﬁeld conditions. However, results are useful to highlight po-
tential losses to test sensitivity should similar conditions be
encountered. Although RDTs evaluated at the site in India
were exposed to high temperatures during transport, it is quite
clear from the parallel assessments in other regions that only 1
of the 4 heat-stressed products (IT LEISH) was less stable after
60 days at 45°C (Supplementary Table 4).
Archived samples were used to avoid the time and expense
associated with prospective sample collection and the com-
plexities of comparing several products simultaneously.
Samples with the fewest freeze-thaw cycles were preferentially
selected, and retested by DAT as an estimate of total antibody
reactivity. Because of limited volumes of sera and restrictions
in shipping of biological specimens internationally, each eval-
uation center assembled its own panel following proﬁciency
testing and sample revalidation using study-speciﬁc standard
operating procedures and materials. The absence of signiﬁcant
differences in test performance within regions supports the
pooling of data and suggests that samples from each laborato-
ry were representative of the patient population in each global
region.
Samples were selected for inclusion if patients were parasi-
tologically conﬁrmed with VL using microscopy or culture of
clinical material (spleen, lymph node, bone marrow). Unfortu-
nately, this is not 100% sensitive and patients with high para-
site burden may have been preferentially selected, which may
have artiﬁcially enhanced clinical accuracy of the RDTs. Fur-
thermore, the majority of controls were healthy individuals
from endemic areas (with negative DAT results) and 10%
were from patients with other disease conditions that mimic
VL. This distribution does not represent the “VL suspect”
population and therefore may overestimate RDT speciﬁcity.
This underlines the importance in clinical practice of combin-
ing RDTs with the WHO clinical case deﬁnition [16] to avoid
false-positive results.
CONCLUSIONS
The 5 RDTs tested in the ISC show high sensitivity and specif-
icity and good lot and reader agreement, and most are heat
stable. RDT sensitivity is more variable in East Africa and
Brazil (Table 3); in Brazil and in 2 sites in East Africa, the
rKE16-based products appeared to perform less well than
rK39 products. Ultimately, outside the ISC, in clinical practice
VL RDT positive results may be adequate to direct treatment
(when combined with the clinical case deﬁnition) but should
be interpreted with caution before excluding a diagnosis of
VL. In all settings, RDTs should be implemented according to
predeﬁned acceptable limits of performance and within an ap-
propriate diagnostic algorithm.
The results of this evaluation may be used to guide procure-
ment and highlight the need for additional research into test
performance among HIV- and VL-coinfected patients and
when used on whole blood rather than serum. Furthermore,
our results should be combined with a detailed ease-of-use
assessment performed in clinical settings to best inform
procurement decisions.
Supplementary Data
Supplementary materials are available at Clinical Infectious Diseases online
(http://www.oxfordjournals.org/our_journals/cid/). Supplementary materi-
als consist of data provided by the author that are published to beneﬁt the
reader. The posted materials are not copyedited. The contents of all
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supplementary data are the sole responsibility of the authors. Questions or
messages regarding errors should be addressed to the author.
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